

Contents lists available at ScienceDirect

Public Health in Practice



journal homepage: www.sciencedirect.com/journal/public-health-in-practice

Original Research

Comorbidity as a predictor of racial and ethnic disparities in cancer in the United States population



Maxwell Akonde^{a,*}, Rajat Das Gupta^a, Ottovon Bismark Dakurah^b, Reston Hartsell^a

^a Department of Epidemiology and Biostatistics, Arnold School of Public Health, University of South Carolina, Columbia, SC, USA ^b African Cancer Institute, Stellenbosch University, South Africa

ARTICLE INFO	A B S T R A C T
Keywords: Comorbidity Racial/ethnic Cancer Adult Disparity	 Aims: This study aims to examine the racial and ethnic disparity in cancer prevalence and determine if comorbidities can explain this disparity. Study design: This was a cross-sectional study. Methods: The study examined cancer prevalence among adults who self-identified as White, Black, and Other races in the US population according to data from the 2017 National Health Interview Survey. Results: Cancer was 58.5% [OR = 0.415; 95% CI: 0.346–0.498] and 57.5% [OR = 0.425; 95%CI: 0.346–0.522] more likely to be found in the White compared to the Black adults and White compared to Other race adults, respectively. After adjusting for the comorbidities, the odds of cancer in White adults increased marginally compared to Black adults [OR = 0.407; 95%CI: 0.338–0.490] and decreased marginally compared to Other race adults [OR = 0.462; 95%CI: 0.374–0.569] even though the odds remained significant. Ever smoking, age of 50 years or more, Former and current alcohol consumption, overweight and obesity, being female and physical inactivity were found to be significantly associated with higher odds of cancer. Conclusions: This study did identify a racial and ethnic disparity in cancer prevalence between White and Black adults and White and Other adult races. However, this racial and ethnic disparity could not be explained by comorbidities.

1. Introduction

Cancer is a leading cause of mortality and morbidity globally with an estimated 1,806,590 new cases and 606,520 deaths occurring in 2020 in the United States (US) [1]. This translates into about 4950 cases diagnosed each day. While the etiology of most cancers is not well understood, multifactorial causes including lifestyle, infections and socioeconomic factors, are said to play a role [2,3]. Hence, cancer prevalence and mortality are affected by these multifactorial causes as well. There is a racial inequality in the prevalence and mortality of cancer cases [4,5]. Although in the last 20 years, there is a declining trend in cancer incidence and mortality, and the incidence in most types of cancers in women are lower in Black women compared to White woman, cancer mortality remains higher in Black compared to White populations[1,6,7]. Because of lower death rates in White populations, the prevalence of cancer appears higher in this race compared to Black populations. While evidence exists on this health disparity, there is insufficient data to adequately explain this variability by race and

ethnicity. Race or ethnicity alone cannot sufficiently explain this disparity either. Race surrogated cancer pathway factors such as socioeconomic factors, access to healthcare, cigarette smoking, alcohol consumption and genetic factors were found to be some explanatory factors for cancer disparities [8–10].

The racial or ethnic disparity in cancer prevalence may also be due to the racial or ethnic distribution of comorbidities. Reducing racial and ethnic disparity in cancer prevalence and mortality entails reducing the race surrogate pathway factors. This involves reducing risk factors including comorbidities. To the best of our knowledge, there is little data from population-based studies examining the role of comorbidities on the racial/ethnic disparity in cancer prevalence in the US population. Therefore, this study was designed to evaluate the relationship between cancer and race and ethnicity using the National Health Interview Survey (NHIS) adult sample data, and to examine if the racial and ethnic disparity in cancer prevalence could be explained or predicted by comorbidities. Establishing this, will help in the realignment of policies on cancer interventions and the appropriate allocation of essential

* Corresponding author.

E-mail address: makonde@email.sc.edu (M. Akonde).

https://doi.org/10.1016/j.puhip.2021.100175

Received 5 September 2020; Received in revised form 15 July 2021; Accepted 30 July 2021 Available online 26 August 2021

2666-5352/© 2021 The Authors. Published by Elsevier Ltd on behalf of The Royal Society for Public Health. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/hty-nc-nd/4.0/).

resources for cancer programs. We hypothesized that the presence of comorbidities may be a predictor of the racial and ethnic disparity in cancer prevalence, hence controlling for known comorbidities would eliminate this disparity.

2. Methods

2.1. Data

This study utilized cross-sectional data of the 2017 National Health Interview Survey (NHIS) to examine the relationship between cancer and race and ethnicity in the US population and how the racial and ethnic cancer disparity is influenced by the distribution of comorbidities among different races. The NHIS is household survey which aims to monitor and update the health of the US population and has been conducted since 1957. The 2017 NHIS included 32.617 households with 66.5% household response rate. A face-to-face interview was conducted from one sample adult from each participating family, and 26,617 of the 33,143 eligible adults were interviewed representing 80.7% response rate. Details of the survey instrument, sampling methodology, and study protocols are published elsewhere [11]. In summary, the 2017 NHIS household survey was designed to consist of a sample of 319 primary sampling units (PSUs) drawn from about 1700 geographically defined PSUs in each of the 50 states and the District of Columbia. A PSU consisted of a county, small group of contiguous counties, or a metropolitan statistical area. The PSUs are stratified by state and subdivided into four separate panels such that each panel is representative of the US civilian noninstitutionalized population. This design is advantageous as it allows flexibility. Each household selected is mailed a letter prior to the visit of a trained interviewer who conducts face-to-face interview. The study utilized a complete case analysis protocol and a weighted sample size of 22,842 was included in the final analysis.

The 2017 NHIS was approved by the Research Ethics Review Board of the National Center for Health Statistics (NCHS) and the US Office of Management and Budget. Additionally, each participant provided an informed consent.

2.2. Study variables

The dependent variable was cancer and was measured as selfreported and dichotomized as "yes" or "no". Participants in the NHIS were asked if they were ever told by a doctor, they had cancer. The independent variables included the following race and ethnicity, comorbidities, and other covariates:

2.3. Independent variables

Race and Ethnicity – Race and ethnicity was the primary predictor variable for this study. Race and ethnicity were self-reported and categorized into (a) White only, (b) Black/African American only, (c) American Indian and Alaskan Native (AIAN) only, (d) Asian only and (e) multiple race. This variable was recoded and categorized into White, Black and Others.

Comorbidities – Comorbidities were the secondary predictor variables which were measured by the presence of other health or disease conditions. The health or disease conditions examined in this study included hypertension, heart attack, stroke, diabetes, weak or failing kidneys, liver conditions, hepatitis, asthma, ulcer, Chronic Obstructive Pulmonary Disease (COPD), sinusitis, angina, other heart conditions, bronchitis, coronary heart disease and hypercholesterolemia. These were self-reported and dichotomized as "yes" or "no". They were treated individually and entered into the model after examining their individual association with the dependent variable.

2.4. Covariates

Sociodemographic variables examined included age, sex, marital status, and employment. Age was measured as a continuous variable but dichotomized as "<50 years" or " ≥50 years" given the risk of cancer in older age [12,13]. Sex was reported as either "Male" or "Female" and both were included in the study. Marital status which was initially reported as "Married (spouse in household)", "married (spouse not in the household)", "married (spouse in household unknown)", "widowed", "divorced", "separated", "Never married" or "Living with partner" was dichotomized as "Married" and "Not married". The employment status was also recoded to examine the impact of employment and unemployment in different races on cancer.

The Body Mass Index (BMI) was determined from the weight and height information that were collected as continuous variables. This was recoded into four categories as Underweight (<18.5kg/m²), Normal weight (18.5kg/m² – 24.9kg/m²), Overweight (25kg/m² - 29.9kg/m²) and Obese (≥ 30 kg/m²) using the Centers for Disease Control and Prevention cut-off points for BMI [14].

Alcohol consumption was measured by the number of drinks within a defined time period and was recoded as "Current drinker", "Former drinker" or "Never drinker". The smoking status was elicited with the question "Ever smoked 100 cigarettes" with "Yes" or "No" response included in the analysis. The responses "refused", "not ascertained" and "do not know" were excluded. Physical activity which was categorized into ten groups was recoded into "Ever exercised" and "Never exercised".

2.5. Statistical analysis

Weighted analysis was performed using SAS version 9.4. Frequencies and percentages were used to describe categorical variables. Chi-square statistic was used to compare the racial differences in the distribution of sociodemographic characteristics such as sex, age, BMI, marital status, physical exercise, smoking status, alcohol drinking status, and employment status. The prevalence of cancer and other comorbidities were also examined across the different races and chi-square comparative analyses were conducted to find out any differences among the racial groups.

Bivariate logistic regression was performed to examine the associations between cancer and the main predictor variable as well as other known risk factors such as smoking status, alcohol status, BMI, physical exercise, age, sex and marital status as crude odds ratios (COR). Similar analyses were performed between cancer and each of the comorbidities. Any covariate yielding a *p*-value <0.05 in the crude analyses was used in the multivariable analyses. This strategy was followed for each interaction term; however no significant association was identified. All analyses were two-sided, with a p-value <0.05 or included confidence intervals not containing the null value of 1 with respect to odd ratios considered statistically significant.

3. Results

The characteristics of the participants are presented in Table 1. A weighted total of 22,842 participants was included with 78.40% being White, 12.29% Black and 9.31% Other races. There were more females (55.01%) than males (47.99%) with most of the participants being <50 years of age (55.07%). Overall, 34.55% of the participants were obese and 32.91% were overweight. There was a higher proportion of Black adults who were obese (44.40%) compared to the Other race adults. Only 33.35% of White adults participated in some form of physical activity. The prevalence of ever smoking and current alcohol drinking was 36.14% and 67.31% respectively. 70.06% of White adults were current drinkers compared to 56.79% of Black adults and 58.01% of Other race adults. More White adults (38.83%) were ever smokers compared to Black adults (26.76%) and Other race adults (25.88%). Unemployment was 5.04% among all participants with White adults (4.38%) having the

Table 1

Characteristics of the participants stratified by the race or ethnicity.

Variable	Total	White	Black	Other	X [2] (df)	p-value
		17908	2808	2126		
		(78.40)	(12.29)	(9.31)		
Sex						
Female	11,879	9191	1563	1125	19.0807	< 0.0001
	(52.01)	(51.32)	(55.66)	(52.93)	(2)	
Male	10,963	8717	1245	1001	(=)	
maie	(47.99)	(48.68)	(44.34)	(47.07)		
Age	(47.55)	(40.00)	(++.5+)	(47.07)		
<50years	12,578	9494	1695	1389	152.9387	< 0.0001
Solvears	(55.07)	(53.02)	(60.36)	(65.34)	(2)	<0.0001
> EOwoor	10,264	(33.02) 8414	1113	(03.34) 737	(2)	
\geq 50years	-					
DM	(44.93)	(46.98)	(39.64)	(34.66)		
BMI	005	000	00	07	066 7000	.0.0001
<18.5	295	220	38	37	266.7882	< 0.0001
10 5 04 0	(1.29)	(1.23)	(1.36)	(1.73)	(6)	
18.5–24.9	7136	5569	681	886		
	(31.24)	(31.10)	(24.26)	(41.70)		
25–29.9	7518	601	842	666		
	(32.91)	(33.57)	(29.97)	(31.32)		
\geq 30	7892	6108	1247	547		
	(34.55)	(34.11)	(44.40)	(25.24)		
Marital Sta						
Married	12,069	9986	918	1166	521.9691	< 0.0001
	(52.84)	(55.76)	(32.70)	(54.82)	(2)	
Not	10,772	7922	1890	960		
Married	(47.16)	(44.24)	(67.30)	(45.18)		
Physical Ac	tivity					
Ever	7556	5973	864	719	7.8522	0.0197
	(33.08)	(33.35)	(30.77)	(33.81)	(2)	
Never	15,286	11,935	1944	1407		
	(66.92)	(66.65)	(69.23)	(66.19)		
Smoke						
Yes	8256	6954	751	550	260.3486	< 0.0001
	(36.14)	(38.83)	(26.76)	(25.88)	(2)	
No	14,586	10,954	2057	1576		
	(63.86)	(61.17)	(73.24)	(74.12)		
Alcohol						
Never	4481	2987	832	663	469.3592	< 0.0001
	(19.62)	(16.68)	(29.63)	(31.16)	(4)	
Current	15,374	12,546	1594	1233		
	(67.31)	(70.06)	(56.79)	(58.01)		
Former	2986	2375	382	230		
	(13.07)	(13.26)	(13.59)	(10.82)		
Job	(10.07)	(10.20)	(10.07)	(10.02)		
Ever	21,693	17,124	2614	1955	77.3410	< 0.0001
Litti	(94.97)	(95.62)	(93.08)	(91.96)	(2)	0.0001
Never	(94.97)	(93.02) 784	(93.08) 194	(91.90) 171	(2)	
ivevei						
	(5.04)	(4.38)	(6.92)	(8.04)		

BMI=Body Mass Index; X [2] - Chi square value; df = degree of freedom.

lowest unemployment value compared to Black adults (6.92%) and Other race adults (6.92%). Irrespective of race, participants who never did any physical activity, never smoked, ever employed and females were statistically higher (as presented in Table 1).

Table 2 presents the analysis on the prevalence of cancer and the comorbidities in the participants. Overall, the prevalence of cancer was 9.24%. Cancer was more prevalent among White adults (10.49%) compared to the Black adults (4.64%) and Other race adults (4.74%). The prevalence of hypertension was 27.95%, with the highest prevalence observed in Black adults (34.97%). Hypercholesterolemia (27.95%) was the most prevalent comorbidity after hypertension (29.63%) in the participants followed by asthma (13.26%) and sinusitis (12.36%). The two least reported comorbidities in the participants were angina (1.64%) and liver conditions (1.74%). Heart attack, angina, coronary heart disease (CHD), other heart conditions, COPD, ulcer and sinusitis were more prevalent in the White adults (3.01%, 1.72%, 4.38%, 8.21%, 3.44%, 6.31% and 13.14% respectively) compared to the Black adults (2.75%, 1.41%, 3.56%, 5.76%, 2.53%, 5.28% and 10.89% respectively) and Other race adults (1.98% and 1.29%, 2.75%, 4.10%, 2.02%, 4.73% and 7.75% respectively). On the other hand, stroke,

Table 2

Prevalence of cancer and other comorbidities in the population stratified by race or ethnicity.

Condition		White	Black	Other	X [2] (df = 2)	P-value
Cancer						
Yes	2110	1879	130	101	155.6766	< 0.000
	(9.24)	(10.49)	(4.64)	(4.74)		
No	20,732	16,029	2678	2025		
	(90.76)	(89.51)	(95.36)	(95.26)		
••	esterolemia	F100	650	E 47	46 7402	-0.000
Yes	6385	5188	650	547	46.7493	< 0.0001
No	(27.95)	(28.97)	(23.13)	(25.74)		
No	16,457	12720	2158	1579		
Hypertensi	(72.05)	(71.03)	(76.87)	(74.26)		
Yes	6767	5255	982	530	61.7434	< 0.000
105	(29.63)	(29.35)	(34.97)	(24.92)	01.7 10 1	0.000
No	16075	12653	1826	1596		
	(70.37)	(70.65)	(65.03)	(75.08)		
Heart Attac		(, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	(*****)	(,)		
Yes	658	539	77	42	7.4353	0.0243
	(2.88)	(3.01)	(2.75)	(1.98)		
No	22184	17369	2731	2084		
	(97.12)	(96.99)	(97.25)	(98.02)		
Stroke						
Yes	696	548	107	42	14.1186	0.0009
	(3.05)	(3.06)	(3.81)	(1.96)		
No	22146	17360	2701	2084		
	(96.95)	(96.94)	(96.19)	(98.04)		
Diabetes						
Yes	2184	1663	312	209	9.6507	0.0080
	(9.56)	(9.29)	(11.12)	(9.8)		
No	20658	16245	2496	1917		
	(90.44)	(90.71)	(88.88)	(90.20)		
Renal cond						
Yes	459	369	65	25	8.8413	0.0120
	(2.01)	(2.06)	(2.30)	(1.18)		
No	22383	17539	2743	2101		
	(97.99)	(97.94)	(97.70)	(98.82)		
Liver condi		014	06	40	(107(0.0400
Yes	397	314	36	48	6.4276	0.0402
No	(1.74) 22445	(1.75) 17594	(1.28) 2772	(2.23) 2078		
NO	(98.26)	(98.25)	(98.72)	2078 (97.77)		
Hepatitis	(90.20)	(90.23)	(90.72)	(97.77)		
Yes	613	482	64	68	3.6719	0.1595
1.00	(2.68)	(2.69)	(2.29)	(3.18)	0.0715	0.1050
No	22229	17426	2744	2058		
	(97.32)	(97.31)	(97.71)	(96.82)		
Asthma		, ,	. ,			
Yes	3030	2407	400	223	17.1375	0.0002
		(10.44)	(14.23)	(10.48)		
	(13.26)	(13.44)				
No	(13.26) 19812	(13.44) 15501	2408	1903		
No				1903 (89.52)		
No Ulcer	19812	15501	2408			
Ulcer	19812	15501	2408		11.5951	0.0030
Ulcer Yes	19812 (86.74) 1379 (6.04)	15501 (86.56) 11300 (6.31)	2408 (85.77) 149 (5.28)	(89.52) 101 (4.73)	11.5951	0.0030
Ulcer Yes	19812 (86.74) 1379	15501 (86.56) 11300 (6.31) 16778	2408 (85.77) 149	(89.52) 101 (4.73) 2025	11.5951	0.0030
Ulcer Yes No	19812 (86.74) 1379 (6.04)	15501 (86.56) 11300 (6.31)	2408 (85.77) 149 (5.28)	(89.52) 101 (4.73)	11.5951	0.0030
Ulcer Yes No C OPD	19812 (86.74) 1379 (6.04) 21463 (93.96)	15501 (86.56) 11300 (6.31) 16778 (93.69)	2408 (85.77) 149 (5.28) 2659 (94.72)	(89.52) 101 (4.73) 2025 (95.27)		
Ulcer Yes	19812 (86.74) 1379 (6.04) 21463 (93.96) 729	15501 (86.56) 11300 (6.31) 16778 (93.69) 615	2408 (85.77) 149 (5.28) 2659 (94.72) 71	(89.52) 101 (4.73) 2025 (95.27) 43	11.5951 16.91183	0.0030
Ulcer Yes No COPD Yes	19812 (86.74) 1379 (6.04) 21463 (93.96) 729 (3.19)	15501 (86.56) 11300 (6.31) 16778 (93.69) 615 (3.44)	2408 (85.77) 149 (5.28) 2659 (94.72) 71 (2.53)	(89.52) 101 (4.73) 2025 (95.27) 43 (2.02)		
Ulcer Yes No COPD Yes	19812 (86.74) 1379 (6.04) 21463 (93.96) 729 (3.19) 22113	15501 (86.56) 11300 (6.31) 16778 (93.69) 615 (3.44) 17293	2408 (85.77) 149 (5.28) 2659 (94.72) 71 (2.53) 2737	 (89.52) 101 (4.73) 2025 (95.27) 43 (2.02) 2083 		
Ulcer Yes No C OPD Yes No	19812 (86.74) 1379 (6.04) 21463 (93.96) 729 (3.19)	15501 (86.56) 11300 (6.31) 16778 (93.69) 615 (3.44)	2408 (85.77) 149 (5.28) 2659 (94.72) 71 (2.53)	(89.52) 101 (4.73) 2025 (95.27) 43 (2.02)		
Ulcer Yes No COPD Yes No Sinusitis	19812 (86.74) 1379 (6.04) 21463 (93.96) 729 (3.19) 22113 (96.81)	15501 (86.56) 11300 (6.31) 16778 (93.69) 615 (3.44) 17293 (96.56)	2408 (85.77) 149 (5.28) 2659 (94.72) 71 (2.53) 2737 (97.47)	 (89.52) 101 (4.73) 2025 (95.27) 43 (2.02) 2083 (97.98) 	16.91183	0.0002
Ulcer Yes No COPD Yes No Sinusitis	19812 (86.74) 1379 (6.04) 21463 (93.96) 729 (3.19) 22113 (96.81) 2824	15501 (86.56) 11300 (6.31) 16778 (93.69) 615 (3.44) 17293 (96.56) 2353	2408 (85.77) 149 (5.28) 2659 (94.72) 71 (2.53) 2737 (97.47) 306	 (89.52) 101 (4.73) 2025 (95.27) 43 (2.02) 2083 (97.98) 165 		0.0002
Ulcer Yes No COPD Yes No Sinusitis Yes	19812 (86.74) 1379 (6.04) 21463 (93.96) 729 (3.19) 22113 (96.81) 2824 (12.36)	15501 (86.56) 11300 (6.31) 16778 (93.69) 615 (3.44) 17293 (96.56) 2353 (13.14)	2408 (85.77) 149 (5.28) 2659 (94.72) 71 (2.53) 2737 (97.47) 306 (10.89)	 (89.52) 101 (4.73) 2025 (95.27) 43 (2.02) 2083 (97.98) 165 (7.75) 	16.91183	0.0002
Ulcer Yes No COPD Yes No Sinusitis Yes	19812 (86.74) 1379 (6.04) 21463 (93.96) 729 (3.19) 22113 (96.81) 2824 (12.36) 20018	15501 (86.56) 11300 (6.31) 16778 (93.69) 615 (3.44) 17293 (96.56) 2353 (13.14) 15555	2408 (85.77) 149 (5.28) 2659 (94.72) 71 (2.53) 2737 (97.47) 306 (10.89) 2502	 (89.52) 101 (4.73) 2025 (95.27) 43 (2.02) 2083 (97.98) 165 (7.75) 1961 	16.91183	0.0002
Ulcer Yes No COPD Yes No Sinusitis Yes No	19812 (86.74) 1379 (6.04) 21463 (93.96) 729 (3.19) 22113 (96.81) 2824 (12.36)	15501 (86.56) 11300 (6.31) 16778 (93.69) 615 (3.44) 17293 (96.56) 2353 (13.14)	2408 (85.77) 149 (5.28) 2659 (94.72) 71 (2.53) 2737 (97.47) 306 (10.89)	 (89.52) 101 (4.73) 2025 (95.27) 43 (2.02) 2083 (97.98) 165 (7.75) 	16.91183	0.0002
Ulcer Yes No COPD Yes Sinusitis Yes No Angina	19812 (86.74) 1379 (6.04) 21463 (93.96) 729 (3.19) 22113 (96.81) 2824 (12.36) 20018 (87.64)	15501 (86.56) 11300 (6.31) 16778 (93.69) 615 (3.44) 17293 (96.56) 2353 (13.14) 15555 (86.86)	2408 (85.77) 149 (5.28) 2659 (94.72) 71 (2.53) 2737 (97.47) 306 (10.89) 2502 (89.11)	 (89.52) 101 (4.73) 2025 (95.27) 43 (2.02) 2083 (97.98) 165 (7.75) 1961 (92.25) 	16.91183 57.3913	0.0002
Ulcer Yes No COPD Yes No Sinusitis	19812 (86.74) 1379 (6.04) 21463 (93.96) 729 (3.19) 22113 (96.81) 2824 (12.36) 20018 (87.64) 375	15501 (86.56) 11300 (6.31) 16778 (93.69) 615 (3.44) 17293 (96.56) 2353 (13.14) 15555 (86.86) 308	2408 (85.77) 149 (5.28) 2659 (94.72) 71 (2.53) 2737 (97.47) 306 (10.89) 2502 (89.11) 40	 (89.52) 101 (4.73) 2025 (95.27) 43 (2.02) 2083 (97.98) 165 (7.75) 1961 (92.25) 28 	16.91183	0.0002
Ulcer Yes No COPD Yes No Sinusitis Yes No Angina Yes	19812 (86.74) 1379 (6.04) 21463 (93.96) 729 (3.19) 22113 (96.81) 2824 (12.36) 20018 (87.64) 375 (1.64)	15501 (86.56) 11300 (6.31) 16778 (93.69) 615 (3.44) 17293 (96.56) 2353 (13.14) 15555 (86.86) 308 (1.72)	2408 (85.77) 149 (5.28) 2659 (94.72) 71 (2.53) 2737 (97.47) 306 (10.89) 2502 (89.11) 40 (1.41)	 (89.52) 101 (4.73) 2025 (95.27) 43 (2.02) 2083 (97.98) 165 (7.75) 1961 (92.25) 28 (1.29) 	16.91183 57.3913	0.0002
Ulcer Yes No COPD Yes No Sinusitis Yes No Angina	19812 (86.74) 1379 (6.04) 21463 (93.96) 729 (3.19) 22113 (96.81) 2824 (12.36) 20018 (87.64) 375 (1.64) 22467	15501 (86.56) 11300 (6.31) 16778 (93.69) 615 (3.44) 17293 (96.56) 2353 (13.14) 15555 (86.86) 308 (1.72) 17600	2408 (85.77) 149 (5.28) 2659 (94.72) 71 (2.53) 2737 (97.47) 306 (10.89) 2502 (89.11) 40 (1.41) 2768	 (89.52) 101 (4.73) 2025 (95.27) 43 (2.02) 2083 (97.98) 165 (7.75) 1961 (92.25) 28 (1.29) 2098 	16.91183 57.3913	0.0002
Ulcer Yes No COPD Yes Sinusitis Yes No Angina Yes No	19812 (86.74) 1379 (6.04) 21463 (93.96) 729 (3.19) 22113 (96.81) 2824 (12.36) 20018 (87.64) 375 (1.64)	15501 (86.56) 11300 (6.31) 16778 (93.69) 615 (3.44) 17293 (96.56) 2353 (13.14) 15555 (86.86) 308 (1.72) 17600 (98.28)	2408 (85.77) 149 (5.28) 2659 (94.72) 71 (2.53) 2737 (97.47) 306 (10.89) 2502 (89.11) 40 (1.41)	 (89.52) 101 (4.73) 2025 (95.27) 43 (2.02) 2083 (97.98) 165 (7.75) 1961 (92.25) 28 (1.29) 	16.91183 57.3913	0.0002

(continued on next page)

Table 2 (continued)

Condition		White	Black	Other	X [2] (df = 2)	P-value
	1719	1470	162	87		
	(7.52)	(8.21)	(5.76)	(4.10)		
No	21123	16438	2646	2039		
	(92.48)	(91.79)	(94.24)	(95.90)		
Bronchitis						
Yes	759	615	101	43	12.6346	0.0018
	(3.32)	(3.44)	(3.58)	(2.01)		
No	22083	17293	2707	2083		
	(96.68)	(96.56)	(96.42)	(97.99)		
CHD						
Yes	944	785	100	59	15.4237	0.0004
	(4.13)	(4.38)	(3.56)	(2.75)		
No	21898	17123	2708	2067		
	(95.87)	(95.62)	(96.44)	(97.25)		

COPD – Chronic Obstructive Pulmonary Disease; CHD – Coronary Heart Disease; X [2] = Chi square value; df = degree of freedom.

diabetes, renal failure, asthma and Bronchitis were more prevalent among the Black adults (3.81%, 11.12%, 2.30%, 14.23% and 3.58%) compared to the White adults (3.06%, 9.29%, 2.06%, 13.44% and 3.32%) and Other race adults (1.96%, 9.80%, 1.18%, 10.48% and 2.01%). Hepatitis and liver conditions were the only two comorbidities more prevalent among Other race adults (hepatitis and liver conditions: 3.18% and 2.23%, respectively) compared to the Black adults (hepatitis and liver conditions: 2.29% and 1.28%, respectively) and White adults (hepatitis and liver conditions: 2.69% and 1.75%, respectively). Apart from angina (p-value = 0.1975) and hepatitis (p-value = 0.1595), significant differences in prevalence were observed across racial and ethnic groups.

From Table 3, hypertension was the most prevalent comorbidity among the cancer subjects with 52.11% of all cancer subjects reported having hypertension. This was followed by hypercholesterolemia with 48.68% of cancer subjects reporting to have high cholesterol. 3.62% and 4.58% of the subjects with cancer compared to only 1.55% and 1.75% in the subjects with no cancer reported some liver and renal conditions, respectively. Diabetes was 15.74% prevalent in the cancer subjects compared to 8.93% in those without cancer whilst CHD was 11.43% among the cancer compared to 3.39% among those without cancer. All comorbidities were significantly higher among those with cancer compared to those without cancer.

Participants who were overweight and obese were 17.8% [OR = 1.178; 95% CI: 1.052–1.319] and 30.0% [OR = 1.30; 95%CI: 1.010–1.265] more likely to have cancer compared to participants with normal weight. Also, participants who smoked and drank alcohol were 79.9% [OR = 1.799; 95% CI: 1.644–1.969] and 23.6% [OR = 1.236; 95% CI: 1.091–1.401] more likely to have cancer compared to participant who did not smoke and drink. Being \geq 50 years (p-value <0.0001), a female (p-value = 0.0058) and married (p-value <0.0001) were significantly associated with cancer prevalence as presented in Table 4.

Cancer was 58.5% [OR = 0.415; 95% CI: 0.346–0.498] and 57.5% [OR = 0.425; 95% CI: 0.346–0.522] more likely to be prevalent in the White adults compared to Black and Other race adults, respectively. After adjusting for all comorbidities the odds of cancer in White adults increased marginally compared to Black adults [OR = 0.407; 95% CI: 0.338–0.490] and decreased marginally compared to Other races [OR = 0.462; 95% CI: 0.374–0.569] even though the odds remained significant as seen in Table 5.

4. Discussion

Cancer remains a significant cause of disability and death globally. Multiple risk factors have been found to be associated with cancer. Race and ethnicity have long been established as a risk factor. However, race and ethnicity have not sufficiently explained the racial disparity in the

Table 3

Prevalence of the	comorbidities	in	the	participants	stratified	by the	cancer
status.							

Comorbidity	Total	Cancer status		X [2](df =	p-value	
		Yes	No	2)		
Hypercholeste	rolemia					
Yes	6385	1027	5358	496.1679	< 0.0001	
	(27.95)	(48.68)	(25.84)			
No	16457	1083	15384			
	(72.05)	(51.32)	(74.16)			
Hypertensior	1					
Yes	6767	1100	5668	563.8648	< 0.0001	
	(29.63)	(52.11)	(27.34)			
No	16075	1011	15064			
	(70.37)	(47.89)	(72.66)			
Heart Attack						
Yes	658(2.88)	143(6.74)	516(2.49)	123.7962	< 0.0001	
No	22184	1968	20216			
	(97.12)	(93.26)	(97.51)			
Stroke						
Yes	696(3.05)	161(7.62)	536(2.58)	164.2301	< 0.0001	
No	22146	1950	20196			
	(96.95)	(92.38)	(97.42)			
Diabetes						
Yes	2184	333	1852	102.5969	< 0.0001	
	(9.56)	(15.74)	(8.93)			
No	20658	1778	18880			
	(90.44)	(84.26)	(91.07)			
Renal conditi						
Yes	459(2.01)	97(4.58)	362(1.75)	78.3828	< 0.0001	
No	22383	2014	20369			
	(97.99)	(95.42)	(98.25)			
Liver conditi	on					
Yes	398(1.74)	77(3.62)	321(1.55)	47.9204	< 0.0001	
No	22444	2034	20410			
	(98.26)	(96.38)	(98.45)			
Hepatitis	(,	(10100)	(10110)			
Yes	614(2.68)	83(3.92)	531(2.56)	13.5436	0.0002	
No	22228	2028	20201			
	(97.32)	(98.08)	(97.44)			
Asthma	()/.02)	(90.00)	()).(1)			
Yes	3030	321	2708	7.7581	0.0053	
105	(13.26)	(15.22)	(13.06)	/./001	0.0000	
No	19812	1789	18023			
NO	(86.74)	(84.78)	(86.94)			
Ulcer	(00.74)	(04.70)	(00.94)			
			1132	131.1620	< 0.0001	
	1270	247		131.1020		
	1379	247			<0.0001	
Yes	(6.04)	(11.69)	(5.46)		<0.0001	
Yes	(6.04) 21463	(11.69) 1863	(5.46) 19599		0.0001	
Yes No	(6.04)	(11.69)	(5.46)		<0.0001	
Yes No C OPD	(6.04) 21463 (93.96)	(11.69) 1863 (88.31)	(5.46) 19599 (94.54)			
Yes No COPD Yes	(6.04) 21463 (93.96) 729(3.19)	(11.69) 1863 (88.31) 166(7.88)	(5.46) 19599 (94.54) 563(2.71)	165.5998		
Yes No COPD Yes	(6.04) 21463 (93.96) 729(3.19) 22113	(11.69) 1863 (88.31) 166(7.88) 1944	(5.46) 19599 (94.54) 563(2.71) 20169		<0.0001	
Yes No COPD Yes No	(6.04) 21463 (93.96) 729(3.19)	(11.69) 1863 (88.31) 166(7.88)	(5.46) 19599 (94.54) 563(2.71)			
Yes No C OPD Yes No Sinusitis	(6.04) 21463 (93.96) 729(3.19) 22113 (96.81)	(11.69) 1863 (88.31) 166(7.88) 1944 (92.12)	(5.46) 19599 (94.54) 563(2.71) 20169 (97.29)	165.5998	<0.0001	
Yes No C OPD Yes No Sinusitis	(6.04) 21463 (93.96) 729(3.19) 22113 (96.81) 2824	(11.69) 1863 (88.31) 166(7.88) 1944 (92.12) 384	(5.46) 19599 (94.54) 563(2.71) 20169 (97.29) 2439		<0.0001	
Yes No COPD Yes No Sinusitis Yes	(6.04) 21463 (93.96) 729(3.19) 22113 (96.81) 2824 (12.36)	(11.69) 1863 (88.31) 166(7.88) 1944 (92.12) 384 (18.21)	(5.46) 19599 (94.54) 563(2.71) 20169 (97.29) 2439 (11.76)	165.5998	<0.0001	
Yes No COPD Yes No Sinusitis Yes	(6.04) 21463 (93.96) 729(3.19) 22113 (96.81) 2824 (12.36) 20018	(11.69) 1863 (88.31) 166(7.88) 1944 (92.12) 384 (18.21) 1726	(5.46) 19599 (94.54) 563(2.71) 20169 (97.29) 2439 (11.76) 18292	165.5998	<0.0001	
Yes No COPD Yes No Sinusitis Yes No	(6.04) 21463 (93.96) 729(3.19) 22113 (96.81) 2824 (12.36)	(11.69) 1863 (88.31) 166(7.88) 1944 (92.12) 384 (18.21)	(5.46) 19599 (94.54) 563(2.71) 20169 (97.29) 2439 (11.76)	165.5998	<0.0001	
Yes No COPD Yes No Sinusitis Yes No Angina	(6.04) 21463 (93.96) 729(3.19) 22113 (96.81) 2824 (12.36) 20018 (87.64)	(11.69) 1863 (88.31) 166(7.88) 1944 (92.12) 384 (18.21) 1726 (81.79)	(5.46) 19599 (94.54) 563(2.71) 20169 (97.29) 2439 (11.76) 18292 (88.24)	165.5998 73.4081	<0.0001	
Yes No COPD Yes No Sinusitis Yes No Angina Yes	(6.04) 21463 (93.96) 729(3.19) 22113 (96.81) 2824 (12.36) 20018 (87.64) 375(1.64)	(11.69) 1863 (88.31) 166(7.88) 1944 (92.12) 384 (18.21) 1726 (81.79) 90(4.25)	(5.46) 19599 (94.54) 563(2.71) 20169 (97.29) 2439 (11.76) 18292 (88.24) 285(1.38)	165.5998	<0.0001	
Yes No COPD Yes No Sinusitis Yes No Angina Yes	(6.04) 21463 (93.96) 729(3.19) 22113 (96.81) 2824 (12.36) 20018 (87.64) 375(1.64) 22467	(11.69) 1863 (88.31) 166(7.88) 1944 (92.12) 384 (18.21) 1726 (81.79) 90(4.25) 2021	(5.46) 19599 (94.54) 563(2.71) 20169 (97.29) 2439 (11.76) 18292 (88.24) 285(1.38) 20446	165.5998 73.4081	<0.0001	
Yes No COPD Yes No Sinusitis Yes No Angina Yes No	(6.04) 21463 (93.96) 729(3.19) 22113 (96.81) 2824 (12.36) 20018 (87.64) 375(1.64) 22467 (98.36)	(11.69) 1863 (88.31) 166(7.88) 1944 (92.12) 384 (18.21) 1726 (81.79) 90(4.25)	(5.46) 19599 (94.54) 563(2.71) 20169 (97.29) 2439 (11.76) 18292 (88.24) 285(1.38)	165.5998 73.4081	<0.0001	
Yes No COPD Yes No Sinusitis Yes No Angina Yes No	(6.04) 21463 (93.96) 729(3.19) 22113 (96.81) 2824 (12.36) 20018 (87.64) 375(1.64) 22467 (98.36)	 (11.69) 1863 (88.31) 166(7.88) 1944 (92.12) 384 (18.21) 1726 (81.79) 90(4.25) 2021 (95.75) 	(5.46) 19599 (94.54) 563(2.71) 20169 (97.29) 2439 (11.76) 18292 (88.24) 285(1.38) 20446	165.5998 73.4081	<0.0001	
Yes No COPD Yes No Sinusitis Yes No Angina Yes No Heart Condit	(6.04) 21463 (93.96) 729(3.19) 22113 (96.81) 2824 (12.36) 20018 (87.64) 375(1.64) 22467 (98.36)	(11.69) 1863 (88.31) 166(7.88) 1944 (92.12) 384 (18.21) 1726 (81.79) 90(4.25) 2021	(5.46) 19599 (94.54) 563(2.71) 20169 (97.29) 2439 (11.76) 18292 (88.24) 285(1.38) 20446	165.5998 73.4081	<0.0001 <0.0001 <0.0001	
Yes No COPD Yes No Sinusitis Yes No Angina Yes No Heart Condit	(6.04) 21463 (93.96) 729(3.19) 22113 (96.81) 2824 (12.36) 20018 (87.64) 375(1.64) 22467 (98.36) ions	 (11.69) 1863 (88.31) 166(7.88) 1944 (92.12) 384 (18.21) 1726 (81.79) 90(4.25) 2021 (95.75) 	(5.46) 19599 (94.54) 563(2.71) 20169 (97.29) 2439 (11.76) 18292 (88.24) 285(1.38) 20446 (98.62)	165.5998 73.4081 97.7889	<0.0001 <0.0001 <0.0001	
Yes No COPD Yes No Sinusitis Yes No Angina Yes No Heart Condit Yes	(6.04) 21463 (93.96) 729(3.19) 22113 (96.81) 2824 (12.36) 20018 (87.64) 375(1.64) 22467 (98.36) ions 1719	(11.69) 1863 (88.31) 166(7.88) 1944 (92.12) 384 (18.21) 1726 (81.79) 90(4.25) 2021 (95.75) 348	(5.46) 19599 (94.54) 563(2.71) 20169 (97.29) 2439 (11.76) 18292 (88.24) 285(1.38) 20446 (98.62) 1371	165.5998 73.4081 97.7889	<0.0001 <0.0001 <0.0001	
Yes No COPD Yes No Sinusitis Yes No Angina Yes No Heart Condit Yes	(6.04) 21463 (93.96) 22113 (96.81) 2824 (12.36) 20018 (87.64) 375(1.64) 22467 (98.36) ions 1719 (7.52)	(11.69) 1863 (88.31) 166(7.88) 1944 (92.12) 384 (18.21) 1726 (81.79) 90(4.25) 2021 (95.75) 348 (16.46)	(5.46) 19599 (94.54) 563(2.71) 20169 (97.29) 2439 (11.76) 18292 (88.24) 285(1.38) 20446 (98.62) 1371 (6.61)	165.5998 73.4081 97.7889	<0.0001 <0.0001 <0.0001	
Yes No COPD Yes No Sinusitis Yes No Angina Yes No Heart Condit Yes No	(6.04) 21463 (93.96) 729(3.19) 22113 (96.81) 2824 (12.36) 20018 (87.64) 375(1.64) 22467 (98.36) ions 1719 (7.52) 21123	(11.69) 1863 (88.31) 166(7.88) 1944 (92.12) 384 (18.21) 1726 (81.79) 90(4.25) 2021 (95.75) 348 (16.46) 1763	(5.46) 19599 (94.54) 563(2.71) 20169 (97.29) 2439 (11.76) 18292 (88.24) 285(1.38) 20446 (98.62) 1371 (6.61) 19360	165.5998 73.4081 97.7889	<0.0001 <0.0001 <0.0001	
Yes No COPD Yes No Sinusitis Yes No Angina Yes No Heart Condit Yes No Bronchitis	(6.04) 21463 (93.96) 729(3.19) 22113 (96.81) 2824 (12.36) 20018 (87.64) 375(1.64) 22467 (98.36) ions 1719 (7.52) 21123	(11.69) 1863 (88.31) 166(7.88) 1944 (92.12) 384 (18.21) 1726 (81.79) 90(4.25) 2021 (95.75) 348 (16.46) 1763	(5.46) 19599 (94.54) 563(2.71) 20169 (97.29) 2439 (11.76) 18292 (88.24) 285(1.38) 20446 (98.62) 1371 (6.61) 19360	165.5998 73.4081 97.7889	<0.0001 <0.0001 <0.0001	
Yes No COPD Yes No Sinusitis Yes No Angina Yes No Heart Condit Yes No Bronchitis Yes	(6.04) 21463 (93.96) 729(3.19) 22113 (96.81) 2824 (12.36) 20018 (87.64) 375(1.64) 22467 (98.36) ions 1719 (7.52) 21123 (92.48) 759(3.32)	(11.69) 1863 (88.31) 166(7.88) 1944 (92.12) 384 (18.21) 1726 (81.79) 90(4.25) 2021 (95.75) 348 (16.46) 1763 (83.54) 121(5.71)	(5.46) 19599 (94.54) 563(2.71) 20169 (97.29) 2439 (11.76) 18292 (88.24) 285(1.38) 20446 (98.62) 1371 (6.61) 19360 (93.39) 638(3.08)	165.5998 73.4081 97.7889 266.9406	<0.0001 <0.0001 <0.0001	
Yes No COPD Yes No Sinusitis Yes No Angina Yes No Heart Condit Yes No Bronchitis Yes	(6.04) 21463 (93.96) 22113 (96.81) 2824 (12.36) 20018 (87.64) 2467 (98.36) ions 1719 (7.52) 21123 (92.48) 759(3.32) 22083	(11.69) 1863 (88.31) 166(7.88) 1944 (92.12) 384 (18.21) 1726 (81.79) 90(4.25) 2021 (95.75) 348 (16.46) 1763 (83.54) 121(5.71) 1990	(5.46) 19599 (94.54) 563(2.71) 20169 (97.29) 2439 (11.76) 18292 (88.24) 285(1.38) 20446 (98.62) 1371 (6.61) 19360 (93.39) 638(3.08) 20093	165.5998 73.4081 97.7889 266.9406	<0.0001 <0.0001 <0.0001	
Yes No COPD Yes No Sinusitis Yes No Angina Yes No Heart Condit Yes No Bronchitis Yes No	(6.04) 21463 (93.96) 729(3.19) 22113 (96.81) 2824 (12.36) 20018 (87.64) 375(1.64) 22467 (98.36) ions 1719 (7.52) 21123 (92.48) 759(3.32)	(11.69) 1863 (88.31) 166(7.88) 1944 (92.12) 384 (18.21) 1726 (81.79) 90(4.25) 2021 (95.75) 348 (16.46) 1763 (83.54) 121(5.71)	(5.46) 19599 (94.54) 563(2.71) 20169 (97.29) 2439 (11.76) 18292 (88.24) 285(1.38) 20446 (98.62) 1371 (6.61) 19360 (93.39) 638(3.08)	165.5998 73.4081 97.7889 266.9406	<0.0001 <0.0001 <0.0001	
Yes No COPD Yes No Sinusitis Yes No Angina Yes No Heart Condit Yes No Bronchitis Yes No	(6.04) 21463 (93.96) 729(3.19) 22113 (96.81) 2824 (12.36) 20018 (87.64) 375(1.64) 22467 (98.36) ions 1719 (7.52) 21123 (92.48) 759(3.32) 22083 (96.68)	 (11.69) 1863 (88.31) 166(7.88) 1944 (92.12) 384 (18.21) 1726 (81.79) 90(4.25) 2021 (95.75) 348 (16.46) 1763 (83.54) 121(5.71) 1990 (94.29) 	(5.46) 19599 (94.54) 563(2.71) 20169 (97.29) 2439 (11.76) 18292 (88.24) 285(1.38) 20446 (98.62) 1371 (6.61) 19360 (93.39) 638(3.08) 20093 (96.92)	165.5998 73.4081 97.7889 266.9406 41.4870	<0.0001 <0.0001 <0.0001 <0.0001	
Yes No COPD Yes No Sinusitis Yes No Angina Yes No Heart Condit Yes No Bronchitis Yes No CHD Yes	(6.04) 21463 (93.96) 22113 (96.81) 2824 (12.36) 20018 (87.64) 2467 (98.36) ions 1719 (7.52) 21123 (92.48) 759(3.32) 22083	(11.69) 1863 (88.31) 166(7.88) 1944 (92.12) 384 (18.21) 1726 (81.79) 90(4.25) 2021 (95.75) 348 (16.46) 1763 (83.54) 121(5.71) 1990 (94.29) 241	(5.46) 19599 (94.54) 563(2.71) 20169 (97.29) 2439 (11.76) 18292 (88.24) 285(1.38) 20446 (98.62) 1371 (6.61) 19360 (93.39) 638(3.08) 20093	165.5998 73.4081 97.7889 266.9406		
Yes No COPD Yes No Sinusitis Yes No Heart Condit Yes No Bronchitis Yes No CHD	(6.04) 21463 (93.96) 729(3.19) 22113 (96.81) 2824 (12.36) 20018 (87.64) 375(1.64) 22467 (98.36) ions 1719 (7.52) 21123 (92.48) 759(3.32) 22083 (96.68)	 (11.69) 1863 (88.31) 166(7.88) 1944 (92.12) 384 (18.21) 1726 (81.79) 90(4.25) 2021 (95.75) 348 (16.46) 1763 (83.54) 121(5.71) 1990 (94.29) 	(5.46) 19599 (94.54) 563(2.71) 20169 (97.29) 2439 (11.76) 18292 (88.24) 285(1.38) 20446 (98.62) 1371 (6.61) 19360 (93.39) 638(3.08) 20093 (96.92)	165.5998 73.4081 97.7889 266.9406 41.4870	<0.0001 <0.0001 <0.0001 <0.0001	

COPD – Chronic Obstructive Pulmonary Disease; CHD – Coronary Heart Disease; X^2 = Chi square value; df = degree of freedom.

Table 4

Risk factors for cancer in the participants.

Covariate	Odd ratio	95% CI	p-value
Smoke			
No	1		
Yes	1.799	1.644-1.969	< 0.0001
Alcohol			
Never	1		
Current	1.236	1.091-1.401	0.0009
Former	2.023	1.736-2.358	< 0.0001
BMI			
Normal	1		
Underweight	0.951	0.620-1.457	0.8166
Overweight	1.178	1.052-1.319	0.0045
Obese	1.130	1.010-1.265	0.0327
Physical Activity			
Never	1		
Ever	1.335	1.208-1.475	< 0.0001
Age			
< 50 years	1		
\geq 50years	8.420	7.440-9.528	< 0.0001
Sex			
Male	1		
Female	1.135	1.037-1.242	0.0058
Marital Status			
Nonmarried	1		
Married	1.564	1.426–1.715	< 0.0001

CI = Confidence Interval.

Table 5 Racial or ethnic disparity in cancer prevalence adjusting for comorbidities.

	Unadjusted	1	Adjusted	
Race	OR	95%CI	OR	95% CI
White	1	Referent	1	Referent
Black	0.415	0.346-0.498	0.407	0.338-0.490
Other	0.425	0.346-0.522	0.462	0.374-0.569

OR = Odd ratio; CI = Confidence Interval.

prevalence, incidence, and mortality of cancer. This study reevaluated some traditional cancer risk factors such as cigarette smoking, age, physical activity, alcohol consumption and body mass index and examined comorbidity as an explanatory variable for the racial and ethnic disparity in cancer using prevalence odds ratios. Ever smoking, age of 50 years or more, former, and current alcohol consumption, overweight and obesity, being female and physical inactivity were found to be significantly associated with higher odds of cancer. There was not enough evidence indicating that comorbidities were a significant predictor of the racial/ethnic disparity in cancer prevalence.

Physical inactivity resulted in 33.5% more cancer cases compared to people who ever exercised. Similar positive associations between the risk of some cancers and physical activity have been reported [15–17]. There are several known mechanisms that establish the impact of physical activity on cancer risk. While some of these mechanisms may be specific to some particular cancers, one unifying mechanism suggest that physical inactivity reduces the sensitivity to insulin thereby leading to a growth promotional environment and hence facilitating neoplasia [17]. Again, physical activity may improve the non-specific immune system which can offer protection against uncontrolled cellular growth. While being underweight was observed to be protective against cancer compared to normal weight, overweight and obese were associated with increased cancer risk. Wang et al., observed 0.65% of cancer cases in the Chinese population was attributable to overweight and obesity combined [18]. Physical activity levels are associated with overweight and obesity outcomes. Physical inactivity leads to gain in weight and

subsequently overweight and/or obesity [19].

People who were 50 years or older were 7.42 times more likely to have cancer compared to those younger than 50 years. Aging comes with a lot of biological and physiological changes including a decline in organ function. Mechanisms involved include telomere attrition, loss of proteostatis, altered metabolism, stem cell function and cellular senescence [20]. Cancer is therefore, considered an aging disease even though the mechanisms remain unclear. Other traditional factors such as ever smoking, alcohol status and sex remained significantly associated with cancer prevalence as observed in previous studies [21-24]. People who ever smoked were 80% more likely to have or have had cancer compared to those who have never. Smoking affects nearly every organ and system of the body thereby reducing the overall health of the person. The carcinogens in the cigarette cause a wearing of the tissues lining the lungs where the cells eventually are forced to act abnormally after a series of repairs. Smoking also leads to inflammation and a reduction in the immune function. Alcohol also causes damages to the body. It can be converted to acetaldehyde, a chemical substance which has the potential to damage the human DNA which can lead to cancer. Thus, this study found that adults who currently drank alcohol were 23.6% more likely to have or have had cancer compared to those who have never consumed any alcohol. Further, former alcohol consumers were 2.023 times as likely to be a cancer case compared to adults who never consumed alcohol.

Comorbidities have long been acknowledged as risk for cancer occurrence and mortality. All comorbidities included in this study were significantly more prevalent in the cancer subjects compared to the no cancer subjects. Hypertension was the most common comorbidity in both groups, followed by hypercholesterolemia. Some drugs used in the treatment of cancer, especially angiogenesis inhibitors, have been found to significantly increase the risk of hypertension[25–27]. Even though the mechanism is not well understood, the drugs used in cancer treatment have anti-vascular endothelial growth factor (VEGF) antibody and certain tyrosine kinase inhibitors associated with endothelial dysfunction due to reduced nitric oxide bioavailability. This can lead to increased vascular and renal endothelin production. Endothelin causes increased vascular tone; decreased density of micro-vessels; and renal thrombotic microangiopathy with secondary glomerular structural and functional changes that lead to proteinuria and hypertension [26].

Cancer was 58.5% and 57.5% more likely in White adults compared to the Black adults and Other race adults, respectively. Cancer prevalence is highest in the White adults because of higher cancer survival rates. Cancer survival in Black adults are lower and mostly attributed to socioeconomic factors including access to healthcare [28,29]. After adjusting for comorbidities, the prevalence odds did not change much and remained significantly different across the different racial and ethnic groups with cancer being 59.3% and 53.8% more likely in White adults compared to Black adults and Other race adults, respectively. This is likely due to the variation in the distribution of different comorbid conditions. For instance, while hypercholesterolemia, heart attack, liver conditions, COPD, hepatitis, ulcer and CHD were significantly higher in White adults compared to the Black adults, hypertension, stroke, diabetes, asthma and renal conditions were significantly higher in the Black adults compared to the White adults.

This study examined the possibility of comorbidity being a predictor of the racial and ethnic disparity in cancer prevalence in the United States. The findings indicate that comorbidities could not explain or predict the reasons for the higher cancer prevalence in the White adults compared to the Black and Other race adults. Again, this study identified traditional cancer risk factors, such as smoking, alcohol consumption, physical inactivity, and age, were significantly associated with cancer prevalence.

While this study has several strengths including the large sample size, the randomization in the data collection and the generalizability of the findings to US populations, there are some limitations. First, the data from the cross-sectional study design limits the ability to know when the development of cancer disparities occurred in the population. Furthermore, the lack of a temporal relationship complicates the interpretation of whether comorbidities such as hypertension, hypercholesterolemia and diabetes occurred before the cancer or vice versa. Again, the race and ethnicity data collected could not be separated into specific races such as African Americans, Caucasians, Hispanics and American Indian and Alaskan Native. Thus, the analyses were limited to the use of Black, White and Other races. As mentioned previously, the cancer and comorbidity data were based on self-reporting and hence could have suffered some misclassification reporting and recall biases especially for the comorbidities. These biases might be non-differential misclassification and therefore are unlikely to influence this study's outcome substantially. Finally, even though the analyses adjusted for all comorbidities that were reported, the list of possible comorbid conditions is inexhaustible and hence residual confounding remained. However, it is unlikely that the study findings are driven solely by residual confounding.

In summary, this study found a racial disparity in cancer prevalence; however, this disparity could not be explained by the presence of comorbidities. Therefore, there is a need to examine other risk factors along with comorbidities to better understand the racial disparity in cancer prevalence in the US.

Funding

None.

Ethical approval

The study did not require any ethical approval since the data was taken from a secondary source which was coded anonymously and not linked to individuals that could be traced.

Financial disclosure

No financial disclosures were reported by the authors of this article.

Declaration of competing interest

None declared.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.puhip.2021.100175.

References

- R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2020, CA A Cancer J. Clin. 70 (1) (2020) 7–30, https://doi.org/10.3322/caac.21590.
- [2] K.H. Sharpe, A.D. McMahon, G.M. Raab, D.H. Brewster, D.I. Conway, Association between socioeconomic factors and cancer risk: a population cohort study in Scotland (1991-2006), PloS One 9 (2) (2014), https://doi.org/10.1371/journal. pone.0089513.
- [3] J. Zabaleta, Multifactorial Etiology of Gastric Cancer, Chapter 10, 2012, https:// doi.org/10.1007/978-1-61779-612-8.
- [4] C.E. Desantis, R.L. Siegel, A.G. Sauer, et al., Cancer statistics for african Americans 2016: progress and opportunities in reducing racial disparities, CA A Cancer J. Clin. (66) (2016) 290–308, https://doi.org/10.3322/caac.21340.

- [5] C.E. Desantis, K.D. Miller, A.G. Sauer, R.L. Siegel, Cancer statistics for african Americans, 2019, CA Canc. J. Clin. 69 (3) (2019) 211–233, https://doi.org/ 10.3322/caac.21555.
- [6] J.O.L. DeLancey, M.J. Thun, A. Jemal, E.M. Ward, Recent trends in black-white disparities in cancer mortality, Canc. Epidemiol. Biomark. Prev. 17 (11) (2008) 2908–2913, https://doi.org/10.1158/1055-9965.EPI-08-0131.
- [7] A.A. Aizer, T.J. Wilhite, M. Chen, et al., Lack of reduction in racial disparities in cancer-specific mortality over a 20-year period, Cancer (May 15) (2014) 1532–1539, https://doi.org/10.1002/cncr.28617.
- [8] X.L. Du, S. Fang, S.W. Vernon, et al., Racial disparities and socioeconomic status in association with survival in a large population-based cohort of elderly patients with colon cancer, Cancer 110 (3) (2007) 660–669, https://doi.org/10.1002/ cncr.22826.
- [9] N.G. Zaorsky, T.M. Churilla, B.L. Egleston, et al., Causes of death among cancer patients, Ann. Oncol. 28 (November 2016) (2017) 400–407, https://doi.org/ 10.1093/annonc/mdw604.
- [10] A.S. Oncol, L.A. Newman, Breast cancer Disparities : socioeconomic factors versus biology, Ann. Surg Oncol. (May) (2017), https://doi.org/10.1245/s10434-017-5977-1.
- [11] National Center for Health Statistics National Health Interview Survey, Public-use data file and documentation. 2018; (June). https://www.cdc.gov/nchs/nhis/dat a-questionnaires-documentation.htm, 2017, 1-107.
- [12] K. Smetana, L. Lacina, P. Szabo, B. Dvoánková, P. Bro2, A. Šedo, Ageing as an important risk factor for cancer, Anticancer Res. 36 (10) (2016) 5009–5017, https://doi.org/10.21873/anticanres.11069.
- [13] M.C. White, D.M. Holman, J.E. Boehm, L.A. Peipins, M. Grossman, S. Jane Henley, Age and cancer risk: a potentially modifiable relationship, Am. J. Prev. Med. 46 (3 SUPPL. 1) (2014) S7–S15, https://doi.org/10.1016/j.amepre.2013.10.029.
- [14] Centers for Disease Control and Prevention, Healthy Weight about adult BMI, Published online, https://www.cdc.gov/healthyweight/assessing/bmi/adult_bmi /index.html, 2020, 1-6.
- [15] R. Cannioto, J.L. Etter, M.J. Lamonte, et al., Lifetime physical inactivity is associated with lung cancer risk and mortality, Canc. Treat Res. Commun. 14 (2018) (2018) 37–45, https://doi.org/10.1016/j.ctarc.2018.01.001.
- [16] T. International, C. Epidemiology, R. Cannioto, et al., The association of lifetime physical inactivity with bladder and renal cancer risk : a hospital-based casecontrol analysis, Canc. Epidemiol. 49 (2017) 24–29, https://doi.org/10.1016/j. canep.2017.04.017.
- [17] A.E. Hardman, Physical activity and cancer risk, Proc. Nutr. Soc. 60 (2001) 107–113, https://doi.org/10.1079/PNS200073.
- [18] D. Wang, W. Zheng, S. Wang, et al., HHS public access, Nutr. Canc. 64 (1) (2015) 48–56, https://doi.org/10.1080/01635581.2012.630166.Estimation.
- [19] K.H. Pietiläinen, J. Kaprio, P. Borg, et al., Physical inactivity and Obesity : a vicious circle, Obesity 16 (2) (2008) 409–414, https://doi.org/10.1038/oby.2007.72.
- [20] J.R. Aunan, W.C. Cho, K. Sø, The biology of aging and Cancer : a brief overview of shared and divergent molecular hallmarks, Age Dis. 8 (5) (2017) 628–642, https:// doi.org/10.14336/2FAD.2017.0103.
- [21] J.L. Watters, Y. Park, A. Hollenbeck, A. Schatzkin, D. Albanes, Cigarette smoking and prostate cancer in a prospective US cohort study, Canc. Epidemiol. Biomark. Prev. 18 (9) (2009) 2427–2436, https://doi.org/10.1158/1055-9965.EPI-09-0252.
- [22] N.D. Freedman, C.C. Abnet, N.E. Caporaso, et al., Impact of changing US cigarette smoking patterns on incident cancer : risks of 20 smoking-related cancers among the women and men of the NIH-AARP cohort, Int. J. Epidemiol. 45 (3) (2016) 846–856, https://doi.org/10.1093/ije/dyv175.
- [23] N.D. Freedman, D.T. Silverman, A.R. Hollenbeck, A. Schatzkin, C.C. Abnet, Association between smoking and risk of bladder cancer among men and women, J. Am. Med. Assoc. 306 (7) (2011) 737–745.
- [24] A. Mashberg, P. Boffetta, R. Winkelman, L. Garfinkel, Tobacco smoking, alcohol drinking, and cancer of the oral cavity and oropharynx among U S. Veterans, Cancer 72 (4) (1993) 1369–1375.
- [25] VB De Souza, E.N. Silva, M.L. Ribeiro, W.D.A. Martins, Hypertension in patients with cancer, Arq. Bras. Cardiol. 104 (3) (2015) 246–252, https://doi.org/10.5935/ abc.20150011.
- [26] E. Mouhayar, A. Salahudeen, Hypertension in cancer patients, Tex. Heart Inst. J. 38 (3) (2011) 263–265.
- [27] W.-X. Qi, F. Lin, Y. Sun, et al., Incidence and risk of hypertension with pazopanib in patients with cancer : a meta-analysis, Canc. Chemother. Pharmacol. 71 (2013) (2013) 431–439, https://doi.org/10.1007/s00280-012-2025-5.
- [28] N.O. Peters, S.T. Massa, K.M. Christopher, R.J. Walker, M.A. Varvares, Race and sex disparities in long - term survival of oral and oropharyngeal cancer in the United States, J. Canc. Res. Clin. Oncol. (2015), https://doi.org/10.1007/s00432-015-2061-8, Published online.
- [29] V.B. Benard, M. Watson, M. Saraiya, et al., Cervical cancer survival in the United States by race and stage (2001-2009): findings from the CONCORD-2 study, Cancer 123 (2017) 5119–5137, https://doi.org/10.1002/cncr.30906.